Literature DB >> 6182983

Depressed natural killer cell activity in patients with hepatocellular carcinoma. In vitro effects of interferon and levamisole.

K Son, M Kew, A R Rabson.   

Abstract

Enriched lymphocytes from patients with primary hepatocellular carcinoma showed considerably reduced natural cytotoxicity against two established hepatoma cell lines and against the myelogenous derived cell line K562, as compared to lymphocytes from normal volunteers or from patients with various nonmalignant liver diseases. The serum of hepatoma patients did not effect normal or patient NK cell activity. When lymphocytes from patients or controls were treated for three hours with human leukocyte interferon, NK cell cell activity was significantly improved. Levamisole did not produce a significant increase in normal NK cytotoxicity but did improve the killing of lymphocytes from patients with hepatocellular carcinoma.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6182983     DOI: 10.1002/1097-0142(19821215)50:12<2820::aid-cncr2820501222>3.0.co;2-#

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  16 in total

1.  Natural killer cell activity in patients with liver cirrhosis relative to severity of liver damage.

Authors:  W L Chuang; H W Liu; W Y Chang; S C Chen; M Y Hsieh; L Y Wang
Journal:  Dig Dis Sci       Date:  1991-03       Impact factor: 3.199

2.  Relationship between general or specific immunoreactivity and prognosis in postoperative patients with hepatocellular carcinoma.

Authors:  H Yamasaki; E Okamoto; T Komatsu; Y Manabe; S Shinka
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

3.  Natural killer activity in patients with chronic hepatitis treated with OK432, interferon, adenine arabinoside and glycyrrhizin.

Authors:  T Wada; T Arima; H Nagashima
Journal:  Gastroenterol Jpn       Date:  1987-06

4.  Natural killer and activated killer activities in chronic liver disease and hepatocellular carcinoma: evidence for a decreased lymphokine-induced activity of effector cells.

Authors:  H Hirofuji; S Kakumu; A Fuji; Y Ohtani; K Murase; H Tahara
Journal:  Clin Exp Immunol       Date:  1987-05       Impact factor: 4.330

5.  Liver transplantation for hepatocellular carcinoma.

Authors:  J McPeake; R Williams
Journal:  Gut       Date:  1995-05       Impact factor: 23.059

6.  Contradictory results in interferon research.

Authors:  G Sonnenfeld
Journal:  Surv Immunol Res       Date:  1984

7.  MRI-monitored transcatheter intra-arterial delivery of SPIO-labeled natural killer cells to hepatocellular carcinoma: preclinical studies in a rodent model.

Authors:  Alexander Y Sheu; Zhuoli Zhang; Reed A Omary; Andrew C Larson
Journal:  Invest Radiol       Date:  2013-06       Impact factor: 6.016

8.  Supernatant derived from a human hepatocellular carcinoma cell line (PLC/PRF/5) depresses natural killer (NK) cell activity.

Authors:  A Keong; J Herman; A R Rabson
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

9.  Recombinant human gamma-interferon in primary hepatocellular carcinoma.

Authors:  A Forbes; P J Johnson; R Williams
Journal:  J R Soc Med       Date:  1985-10       Impact factor: 5.344

10.  Deficient immune function of peripheral blood mononuclear cells from patients with Gardner syndrome.

Authors:  R P Warren; A M Stembridge; E J Gardner
Journal:  Clin Exp Immunol       Date:  1985-06       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.